Cachexia Starts in the Brain

01The evidence

• Neural mechanisms of cancer cachexia have been characterised, with hypothalamic circuits regulating appetite and metabolism implicated in the wasting syndrome.PMC review
• Tumour-induced orexigenic imbalance was shown to lower protein appetite and drive early organ-wasting symptoms, which places the drive to eat upstream of the wasting.Nature Communications, 2026

02The tension

Cachexia is explained as a metabolic consequence of the tumour competing for nutrients and of inflammation driving proteolysis. That account predicts wasting should track tumour burden, and it does not: small tumours can cause severe wasting, and large ones sometimes do not.

03The theory

The hypothalamus integrates signals about energy status and sets appetite and substrate use. Tumour-derived and inflammatory signals act on that circuitry, shifting the set point toward catabolism and away from protein intake.

If the set point is shifted, the body behaves as if it were starving even when food is available. Wasting follows from the programme rather than from scarcity, which is why feeding alone does not reverse it.

The prediction is that hypothalamic signalling changes should precede measurable weight loss, and that interventions targeting the circuitry should preserve lean mass without altering tumour size. That is testable in models and in imaging of hypothalamic function.

The clinical consequence is that cachexia should be treated as a neurological syndrome with metabolic consequences, and that appetite-regulating drugs could be disease-modifying rather than supportive.

04What this is not

05Predictions

• P1Hypothalamic signalling should change before weight loss is measurable.
• P2Circuit-targeted interventions should preserve lean mass without shrinking the tumour.
• P3Wasting should not track tumour burden across patients.

06What would refute it

Wasting tracking tumour burden and reversing with feeding would leave the metabolic account adequate.

07What it would change

It would make cachexia a neurological target, and change trial endpoints.